Curacle Co., Ltd. 365270

KRX · South Korea · Health Technology

KRW 10,200.00-180.00 (-1.73%)

Market closed· Oct 2, 2026, 6:30 AM UTC· KRW · Data may be delayed

Prices may be delayed and are for informational purposes only - not investment advice.

Curacle Co., Ltd. 365270

KRX · South Korea · Health Technology

KRW 10,200.00-180.00 (-1.73%)

Market closed· Oct 2, 2026, 6:30 AM UTC· KRW · Data may be delayed

Prices may be delayed and are for informational purposes only - not investment advice.

-26.51% · 6MFull-screen chart

Open KRW 10,460.00High KRW 10,460.00Low KRW 10,020.00Close KRW 10,200.00Volume 42.38K

Oct 2, 2026

Charts by TradingView Lightweight Charts

Key statistics

Previous close: KRW 10,380.00
Day range: KRW 10,020.00 – KRW 10,460.00
52-week range: KRW 4,400.00 – KRW 20,750.00
Volume: 42.38K
Market cap: KRW 229.99B
Avg. volume (1Y): 346.63K

Performance

1 week

+9.62%

1 month

+2.61%

3 months

-8.62%

6 months

-23.19%

Year to date

+29.58%

1 year

+61.34%

Total return, dividends included.

Company profile

Sector: Health Technology
Industry: Pharmaceuticals: Major
Country: South Korea
Exchange: KRX
Shares outstanding: 22.16M
Employees: 31
ISIN: KR7365270008
Beta: 1.31

Technical view

Mixed

Where the price sits against its 50- and 200-day moving averages.

Valuation & analysis

Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.

News

Yahoo FinanceJun 18, 2026

Memento Medicines Launches with $93 Million Series A Financing to advance Tie2 Agonist and VEGF Inhibitor Bispecific Antibody Therapy for Retinal Diseases

Lead program, MMT-205, licensed from MabTics Co., Ltd / Curacle Co., Ltd. is a potential best-in-class bispecific antibody which activates Tie2 and inhibits VEGF, in development for neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME)In connection with the transaction, Memento Medicines has closed a $93M Series A financing, co-led by Forbion, RA Capital Management and Avego BioScience Capital, to support the progress of MMT-205 through IND-enabling and clinical st

Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.